Evidence map›Paper›PMID 29901096›Full record

ArticleInternational journal of molecular medicine2018

Telomerase reverse transcriptase interference synergistically promotes tumor necrosis factor‑related apoptosis‑inducing ligand‑induced oral squamous cell carcinoma apoptosis and suppresses proliferation in vitro and in vivo.

Xin Zhao, Cuicui Zhang, Zhiliang Le, Suyun Zeng, Chaobin Pan, Jianjie Shi, Jianguang Wang, Xiaopeng Zhao

Open access · hybridAbstract read
In one paragraph

Article in International journal of molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Narra J · 2025
    Article
  2. Article
  3. Optimal delivery of RNA interference by viral vectors for cancer therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2023
    Review
  4. Article
  5. Telomerase gene therapy: a remission toward cancer.Medical oncology (Northwood, London, England) · 2022
    Review
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 1 country.

Xin ZhaoDepartment of Stomatology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510150, P.R. China.
Cuicui ZhangKey Laboratory of Oral Medicine, Guangzhou Institute of Oral Disease, Stomatology Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510140, P.R. China.
Zhiliang LeDepartment of Stomatology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong 510635, P.R. China.
Suyun ZengDepartment of Periodontology, Hefei Stomatological Hospital, Hefei, Anhui 230001, P.R. China.
Chaobin PanDepartment of Oral and Maxillofacial Surgery, Sun Yat‑sen Memorial Hospital, Sun Yat‑sen University, Guangzhou, Guangdong 510120, P.R. China.
Jianjie ShiDepartment of Stomatology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510150, P.R. China.
Jianguang WangDepartment of Oral and Maxillofacial Surgery, Sun Yat‑sen Memorial Hospital, Sun Yat‑sen University, Guangzhou, Guangdong 510120, P.R. China.
Xiaopeng ZhaoDepartment of Oral and Maxillofacial Surgery, Sun Yat‑sen Memorial Hospital, Sun Yat‑sen University, Guangzhou, Guangdong 510120, P.R. China.
Sun Yat-sen University · CNGuangzhou Medical University · CNStomatology Hospital · CNSun Yat-sen Memorial Hospital · CNThird Affiliated Hospital of Guangzhou Medical University · CNThird Affiliated Hospital of Southern Medical University · CNTianjin Stomatological Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor necrosis factor‑related apoptosis‑inducing ligand (TRAIL) is known to induce cell apoptosis in many types of cancer cells. However, some malignant cells still exhibit anti‑apoptosis features induced by TRAIL; thus the underlying mechanisms that regulate sensitivity and resistance of tumor cells to TRAIL‑induced apoptosis remain unclear. Human telomerase reverse transcriptase (hTERT) is overexpressed in most types of human tumors and is mostly inactive in somatic cells. The present study aimed to investigate the endogenous effects and mechanisms of hTERT inhibition and TRAIL overexpression on TRAIL‑induced apoptosis of human oral squamous cell carcinoma (OSCC) cells. The effects of adeno‑associated virus (AAV)‑mediated TRAIL and hTERT gene silencing by RNA interference were investigated on the proliferation and apoptosis of human OSCC cells in vitro and in vivo. The present results suggest that knockdown of hTERT expression accelerated TRAIL‑resistant OSCC cells to TRAIL‑induced apoptosis and impaired OSCC cell proliferation. In addition, this process is accompanied by the upregulation of caspase‑3, caspase‑8 and caspase‑9, and downregulation of B cell lymphoma‑2. Additionally, the possible mechanisms underlying the association between TRAIL expression and hTERT silencing were explored. The results demonstrated that TRAIL expression levels were elevated when the hTERT gene was silenced, and notable anti‑tumor effects were observed when TRAIL upregulation and hTERT gene silencing were carried out simultaneously. The present findings provide experimental evidence for the combined use of TRAIL and hTERT as a possible gene therapy strategy in oral cancer.

Indexed as

AnimalsApoptosisCaspase 3Caspase 8Caspase 9Cell CycleCell Line, TumorCell ProliferationCell SurvivalHumansImmunohistochemistryLymphoma, B-CellMiceMice, Inbred BALB CMice, NudeTelomeraseCaspase 3Caspase 8Caspase 9TelomeraseTERT protein, humanTNF-Related Apoptosis-Inducing Ligand

Identifiers

PMID29901096
PMCPMC6089774
OpenAlexW2806679769

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.